XML 48 R11.htm IDEA: XBRL DOCUMENT v2.4.1.9
Segment and Related Information
 6 Months Ended
Dec. 31, 2014
Segment and Related Information
(6) Segment and Related Information

The Company’s business units have been aggregated into three reportable segments: (i) research, (ii) molecular diagnostics and (iii) pharmaceutical and clinical services. The research segment is focused on the discovery of genes, biomarkers and proteins related to major common diseases and includes corporate services such as finance, human resources, legal, and information technology. The molecular diagnostics segment provides testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The pharmaceutical and clinical services segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries. The Company evaluates segment performance based on results from operations before interest income and expense and other income and expense.

Segment revenue and operating income (loss) were as follows during the periods presented:

 

(In thousands)    Molecular
diagnostics		      Pharmaceutical &
clinical services		     Research     Total  

Three months ended December 31, 2014:

          

Revenue

    $ 179,149         5,244        —        $ 184,393   

Depreciation and amortization

      4,991         450        595        6,036   

Segment operating income (loss)

      59,017         (1,011 )      (21,664 )      36,342   

Three months ended December 31, 2013:

          

Revenue

    $ 196,158         7,902        —        $ 204,060   

Depreciation and amortization

      1,467         489        482        2,438   

Segment operating income (loss)

      98,233         1,052        (16,286 )      82,999   

Six months ended December 31, 2014:

          

Revenue

    $ 343,656         9,574        —        $ 353,230   

Depreciation and amortization

      9,969         899        1,122        11,990   

Segment operating income (loss)

      104,101         (2,794 )      (39,045 )      62,262   

Six months ended December 31, 2013:

          

Revenue

    $ 389,144         17,383        —        $ 406,527   

Depreciation and amortization

      2,830         989        992        4,811   

Segment operating income (loss)

      195,981         2,889        (32,967 )      165,903   

 

     Three months ended     Six months ended  
     December 31,     December 31,  
(In thousands)    2014      2013     2014      2013  

Total operating income for reportable segments

    $ 36,342       $ 82,999      $ 62,262       $ 165,903   

Interest income

      85         1,330        140         2,691   

Other

      1,513         (185 )      1,416         (623 ) 

Income tax provision

      13,909         33,784        23,805         62,146   
  

 

 

     

 

 

    

 

 

     

 

 

  

Net income

    $ 24,031       $ 50,360      $ 40,013       $ 105,825